Similarly, rapamycin effectively inhibits the proliferation of lymphoma cells by inactivating the mTORC1/RPS6 signaling pathway and downregulating the expression of phosphorylated RPS6.35 PIK3CA mutations are common in some cancers. This evidence concerns the gene RPS6 and lymphoma.